Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8501819 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(2 years from now) | |
US9382191 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(2 years from now) | |
US8450375 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(2 years from now) | |
US8501818 | HELSINN | Stabilized compositions of alkylating agents and methods of using same |
Mar, 2026
(2 years from now) | |
US7838564 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Mar, 2026
(2 years from now) | |
US7872050 | HELSINN | Stabilized compositions of volatile alkylating agents and methods of using thereof |
Jul, 2029
(6 years from now) |
Drugs and Companies using MECHLORETHAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Alkylating drug indicated for the topical treatment of stage ia and ib mycosis fungoides-type cutaneous t-cell lymphoma in patients who have received prior skin directed therapy
Dosage: GEL;TOPICAL
20
United States
3
Denmark
3
Slovenia
3
Lithuania
3
Hungary
3
Portugal
3
Spain
3
Poland
3
China
3
New Zealand
3
European Union
2
Croatia
2
Japan
1
Turkey
1
Australia
1
Hong Kong
1
Cyprus
1
Korea, Republic of
1
Luxembourg
1
Canada
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic